Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corbus Pharmaceuticals ( (CRBP) ) has shared an announcement.
On April 14, 2026, Corbus Pharmaceuticals announced that the last patient had been enrolled and completed the first clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping the 16-week dose-finding study on schedule for completion in summer 2026. The trial, conducted at multiple U.S. sites, is a double-blind, placebo-controlled study in 240 obese, non-diabetic participants testing once-daily oral doses of 20 mg, 40 mg and 60 mg with dose titration over three months of treatment plus one month of follow-up.
CRB-913 is a non-incretin, highly peripherally restricted oral CB1 inverse agonist positioned as an alternative mechanism for weight loss and long-term weight management, amid high intolerance and discontinuation rates seen with GLP-1 and other incretin therapies. Earlier Phase 1a data completed in December 2025 showed that obese participants on CRB-913 at 150 mg/day achieved a mean 2.9% placebo-adjusted weight loss by Day 14 with a favorable safety and gastrointestinal profile, suggesting potential competitive differentiation in the increasingly crowded obesity drug market.
The most recent analyst rating on (CRBP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, larger 2025 losses and cash burn). Offsets include strong technical strength (price above key moving averages with positive momentum) and supportive corporate developments (FDA alignment and ongoing pipeline catalysts), while valuation is constrained by the company’s current loss-making status and no dividend.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies in oncology and obesity, using innovative approaches to well-understood biological pathways. Its pipeline includes CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4-expressing tumors, and CRB-913, an orally delivered peripherally restricted CB1 inverse agonist for obesity, with headquarters in Norwood, Massachusetts.
The company focuses on bringing new treatment options to patients with serious illnesses, particularly where current standards of care leave significant unmet needs. Corbus is listed on Nasdaq under the ticker CRBP and conducts its clinical programs primarily in the United States across multiple investigative sites and study cohorts.
Average Trading Volume: 192,003
Technical Sentiment Signal: Sell
Current Market Cap: $173.8M
See more insights into CRBP stock on TipRanks’ Stock Analysis page.